Diaceutics PLC
LSE:DXRX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/S
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Valuation Scenarios
If EV/S returns to its 3-Year Average (3.2), the stock would be worth GBX140.58 (19% downside from current price).
| Scenario | EV/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 4 | GBX172.5 |
0%
|
| 3-Year Average | 3.2 | GBX140.58 |
-19%
|
| 5-Year Average | 3.5 | GBX153.25 |
-11%
|
| Industry Average | 0 | GBX0.16 |
-100%
|
| Country Average | 0 | GBX0.18 |
-100%
|
Forward EV/S
Today’s price vs future revenue
| Today's Enterprise Value | Revenue | Forward EV/S | ||
|---|---|---|---|---|
|
GBX117.3m
|
/ |
Jul 2025
£34.4m
|
= |
|
|
GBX117.3m
|
/ |
Dec 2025
£38.9m
|
= |
|
|
GBX117.3m
|
/ |
Dec 2026
£48.4m
|
= |
|
|
GBX117.3m
|
/ |
Dec 2027
£58.7m
|
= |
|
|
GBX117.3m
|
/ |
Dec 2028
£73.6m
|
= |
|
Forward EV/S shows whether today’s EV/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | EV/S | P/E | ||||
|---|---|---|---|---|---|---|
| UK |
|
Diaceutics PLC
LSE:DXRX
|
145.9m GBP | 4 | -96 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
958.5B USD | 336.2 | 3 973.8 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
173.9B USD | 4.7 | 25.5 | |
| US |
|
Danaher Corp
NYSE:DHR
|
127.8B USD | 5.6 | 34.3 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 17.9 | 46.1 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
299.9B CNY | 5.8 | 15.7 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
33.5B CHF | 5.6 | -120.2 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
32.7B USD | 4.8 | 25.2 | |
| US |
|
Waters Corp
NYSE:WAT
|
29.4B USD | 9.4 | 45.9 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
27.8B USD | 2.4 | 19.9 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
26B USD | 6.9 | 29.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0 |
| Median | 0 |
| 70th Percentile | 0 |
| Max | 3 279.7 |
Other Multiples
Diaceutics PLC
Glance View
Diaceutics Plc engages in the provision of data, data analytics and implementation services. The company is headquartered in Belfast, Northern Ireland. The company went IPO on 2019-03-21. The principal activity of the Company is data analytics and implementation services. The firm is engaged in research and development activities in drug development science, testing data and software platform development. The firm's implementation services include test standardization, test quality assessment, laboratory tech support and others. The firm has established a range of products and outsourced advisory services, which help its pharma clients to optimize and deliver their marketing and implementation strategies for companion diagnostics. The firm provides the pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network. DXRX is the diagnostic commercialization platform for precision medicine, integrating multiple pipelines of diagnostic testing data from a global network of laboratories.
